Older Americans bore the brunt of antibiotic-resistant infections, study finds

Older Americans were disproportionately affected by several different types of infection for which antibiotics were largely ineffective, resulting in nearly 12,000 deaths and costing the U.S. health care system almost $1.9 billion in 2017, a new study found.

Of those deaths, 40% were estimated to have occurred among those 65 years and older, while this...

Older Americans bore the brunt of antibiotic-resistant infections, study finds Continue reading…

U.S. Hospitals Lose Legal Challenge to Trump Price Transparency Rule

A federal judge on Tuesday dismissed a challenge by hospital groups to a federal rule requiring them to disclose prices they quietly negotiate with insurers, in a victory for White House efforts to make healthcare pricing more transparent to patients. Read more. 

Regeneron Funneled Kickbacks Through a Patient Charity, Federal Lawsuit Claims

The drugmaker Regeneron funneled tens of millions of dollars to a charity that paid the out-of-pocket costs for patients who took the company’s expensive eye drug, then lied to internal auditors about it, according to a lawsuit filed Wednesday by federal prosecutors in Massachusetts.

The suit, filed in the U.S. District Court of Massachusetts in...

Regeneron Funneled Kickbacks Through a Patient Charity, Federal Lawsuit Claims Continue reading…

Drug firms offer to settle U.S. opioid suits with $50 billion package: sources

Five drugmakers and distributors are offering $22 billion in cash as well as drugs and services they value at $28 billion to resolve lawsuits alleging the industry fueled the U.S. opioid crisis, two sources familiar with the matter said on Wednesday.

The drug industry faces roughly 2,600 lawsuits brought by state and local governments, hospitals...

Drug firms offer to settle U.S. opioid suits with $50 billion package: sources Continue reading…

Celgene settles antitrust lawsuit over cancer drugs for $55 million

Celgene Corp has agreed to pay $55 million to resolve claims that the drugmaker engaged in an multi-faceted scheme to maintain a monopoly over the market for its cancer treatment drugs Thalomid and Revlimid and delay generic competition.

The settlement was disclosed in a filing on Wednesday in federal court in Newark, New Jersey, and...

Celgene settles antitrust lawsuit over cancer drugs for $55 million Continue reading…

U.S. group says Novartis MS drug price out of line with benefit

A U.S. group that reviews the value of medicines issued a critical report on Novartis’s new multiple sclerosis drug Mayzent, calling its $88,561 list price “far out of line” compared with its benefits for patients.

Read More

 

The Death of Antibiotics: We’re Running Out of Effective Drugs to Fight Off an Army of Superbugs

In January, Columbia University revealed that four patients at its Irving Medical Center in New York had been sick with an unusual version of E. coli , a common gut bacterium. Although the news largely escaped attention in the media, it ricocheted through the world of infectious disease experts. E. coli is a relatively...

The Death of Antibiotics: We’re Running Out of Effective Drugs to Fight Off an Army of Superbugs Continue reading…